Our drug development team is dedicated to unraveling the intricate molecular mechanisms underlying the action of drugs and bioactive compounds. We employ automated processes alongside cutting-edge proteomics technology to investigate the dynamic alterations in protein expression and post-translational modifications within biological disease models, including cancer cell lines, in response to drug perturbations. We aim to identify promising biomarkers that correlate with drug sensitivity and critical drug targets. By harnessing the predictive power of artificial intelligence, we strive to forecast drug sensitivities and the synergistic potential of drug combinations, thereby expediting the development of potent therapeutic agents and their efficacious combinations.